Clinical Trial Update: Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 exploratory trial assessing safety and immunogenicity of Menactra and Menomune in people aged 56 and older; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections
• Meningococcal Meningitis

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))
• Menomune (Meningococcal polysaccharide vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Infections, Meningococcal Meningitis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-03-25